Oppenheimer Assumes Cyclacel Pharmaceuticals (CYCC) at Outperform
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Oppenheimer analyst Jeff Jones assumes coverage on Cyclacel Pharmaceuticals (NASDAQ: CYCC) with a Outperform rating and a price target of $17.00.
For an analyst ratings summary and ratings history on Cyclacel Pharmaceuticals click here. For more ratings news on Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $1.22 yesterday.
You May Also Be Interested In
- Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
